The prevalence and economic impact of prescription opioid-related side effects among patients with chronic noncancer pain

Journal of Opioid Management

Volumn 9, Issue 4, 2013, Pages 239-254

  Ivanova, Jasmina I ^a   Birnbaum, Howard G ^a   Yushkina, Yana ^a   Sorg, Rachael A ^a   Reed, John ^b   Merchant, Sanjay ^c  

^a ANALYSIS GROUP   (United States)

^b Reliant Medical Group   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Chronic noncancer pain; Costs; Opioid related side effects; Prescription opioids; Prevalence; Resource use

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; CODEINE; CORTICOSTEROID; HYDROCODONE; HYDROMORPHONE; LAXATIVE; MORPHINE; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; OXYMORPHONE; PARACETAMOL; PRESCRIPTION DRUG; TAPENTADOL; TRAMADOL;

ABDOMINAL PAIN; ADULT; ANALGESIA; ARTICLE; BACKACHE; CANCER PAIN; CHRONIC NONCANCER PAIN; CHRONIC PAIN; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DROWSINESS; DRUG COST; DRUG INDUCED HEADACHE; DRUG SAFETY; ECONOMIC ASPECT; FATIGUE; FEMALE; FIBROMYALGIA; FOOT PAIN; HAND PAIN; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIP PAIN; HUMAN; INTESTINE OBSTRUCTION; IRRITABLE COLON; KNEE PAIN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL DISEASE; MIGRAINE; NAUSEA; NEUROPATHIC PAIN; OSTEOARTHRITIS; PRESCRIPTION; PRURITUS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SELF REPORT; SLEEP DISORDER; THINKING IMPAIRMENT; THORAX PAIN; UNSPECIFIED SIDE EFFECT; VOMITING;

ADULT; AGED; ANALGESICS, OPIOID; CHI-SQUARE DISTRIBUTION; CHRONIC PAIN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEALTH CARE COSTS; HEALTH CARE SURVEYS; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; LOGISTIC MODELS; MALE; MASSACHUSETTS; MEDICAL RECORDS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRESCRIPTION DRUGS; PREVALENCE; TIME FACTORS;

EID: 84886663579     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2013.0165     Document Type: Article

References (30)

1. Noble M, Treadwell JR, Tregear SJ, et al.: Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010; (1): CD006605.
2. Institute of Medicine of the National Academies: Relieving pain in America: A blueprint for transforming prevention, care, education, and research. Available at www.iom.edu/Reports/2011/Relieving-Pain-in-America-A-Blueprint- for-Transforming-Prevention-Care-Education-Research.aspx. Accessed December 6, 2012.
3. Johannes CB, Le TK, Zhou X, et al.: The prevalence of chronic pain in United States adults: Results of an internet-based survey. J Pain. 2010; 11(11): 1230-1239.
4. Chapman RC, Lipschitz DL, Angst MS, et al.: Opioid pharmacotherapy for chronic non-cancer pain in the United States: A research guideline for developing an evidence-base. J Pain. 2010; 11(9): 807-829.
5. Sullivan MD, Edlund MJ, Fan MY, et al.: Trends in use of opioids for non-cancer pain conditions 2000-2005 in Commercial and Medicaid insurance plans: The TROUP study. Pain. 2008; 138: 440-449.
6. Trescot AM, Helm S, Hansen H, et al.: Opioids in the management of chronic non-cancer pain: An update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician. 2008; 11(2 Suppl): S5-S62. (Pubitemid 351682078)
7. Kalso E, Edwards JE, Moore RA, et al.: Opioids in chronic non-cancer pain: Systematic review of efficacy and safety. Pain. 2004; 112(3): 372-380. (Pubitemid 39550738)
8. Moore RA, McQuay HJ: Prevalence of opioid adverse events in chronic non-malignant pain: Systematic review of randomised trials of oral opioids. Arthritis Res Ther. 2005; 7: R1046-R1051.
9. Tuteja AK, Biskupiak J, Stoddard GJ, et al.: Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motil. 2010; 22: 424-e96.
10. Chan BKB, Tam LK, Wat CY, et al.: Opioids in chronic non-cancer pain. Expert Opin Pharacother. 2011; 12(5): 705-720.
11. Sullivan MD, Von Korff M, Banta-Green C, et al.: Problems and concerns of patients receiving chronic opioid therapy for chronic non-cancer pain. Pain. 2010; 149: 345-353.
12. Atluri S, Akbik H, Sudarshan G: Prevention of opioid abuse in chronic non-cancer pain: An algorithmic, evidence based approach. Pain Physician. 2012; 15: ES177-ES189.
13. Annemans L: Pharmacoeconomic impact of adverse events of long-term opioid treatment for the management of persistent pain. Clin Drug Investig. 2011; 31(2): 73-86.
14. Manchikanti L, Helm S, Fellows B, et al.: Opioid epidemic in the United States Pain Physician. 2012; 15: ES9-ES38.
15. Candiotti KA, Gitlin MC: Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: Tapentadol, a step toward a solution? Curr Med Res Opin. 2010; 26: 1677-1684.
16. Summers KH, Puenpatom RA, Rajan N, et al.: Economic impact of potential drug-drug interactions in opioid analgesics. J Med Econ. 2011; 14(4): 390-396.
17. Rauck RL: What is the case for prescribing long-acting opioids over short-acting opioids for patients with chronic pain? A critical review. Pain Pract. 2009; 9(6): 468-479.
18. Nicholson B: Benefits of extended-release opioid analgesic formulations in the treatment of chronic pain. Pain Pract. 2008; 9(1): 71-81.
19. Jonsson T, Christrup LL, H?jsted J, et al.: Symptoms and side effects in chronic non-cancer pain: Patient report vs. systematic assessment. Acta Anaesthesiol Scand. 2011; 55: 69-74.
20. Neighbors DM, Bell TJ, Wilson J, et al.: Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. J Pain Symptom Manage. 2001; 21(2): 129-143. (Pubitemid 32156943)
21. Anastassopoulos KP, Chow W, Tapia Cl, et al.: Economic study on the impact of side effects in patients taking oxycodone controlled-release for noncancer pain. J Manag Care Pharm. 2012; 18(8): 615-626.
22. Iyer S, Davis KL, Candrilli S: Opioid use patterns and health care resource utilization in patients prescribed opioid therapy with and without constipation. Manag Care. 2010; 19(3): 44-51.
23. Kwong WJ, Diels J, Kavanagh S: Costs of gastrointestinal events after outpatient opioid treatment for non-cancer pain. Ann Pharmacother. 2010; 44(4): 630-640.
24. Charlson ME, Pompei P, Ales KL, et al.: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987; 40(5): 373-383. (Pubitemid 17055592)
25. Romano PS, Roos LL, Jollis J: Adapting a clinical comorbidity index for use with ICD-9-CM administrative data. J Clin Epidemiol. 1993; 46(10): 1075-1079.
26. Boswell K, Kwong WJ, Kavanagh S: Burden of opioid-associated gastrointestinal side effects from clinical and economic perspectives: A systematic literature review. J Opioid Manag. 2010; 6(4): 269-289.
27. Gregorian RS Jr, Gasik A, Kwong WJ, et al.: Importance of side effects in opioid treatment: A trade-off analysis with patients and physicians. J Pain. 2010; 11(11): 1095-1108.
28. Gudin J: Opioid therapies and cytochrome p450 interactions. J Pain Symptom Manage. 2012; 44(6 Suppl): S4-14.
29. Braden JB, Russo J, Fan MY, et al.: Emergency department visits among recipients of chronic opioid therapy. Arch Int Med. 2010; 170(16): 1425-1432.
30. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality: The DAWN Report: Highlights of the 2010 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits. Available at http://www.samhsa.gov/data/2k12/DAWN096/ SR096EDHighlights2010.pdf. Accessed April 5, 2013.